Where I digress majorly is that I do not think the trials will take 3 years. I believe it will be far smaller and less expensive than many think, as OSL management are focused on working with the FDA to target shrinkage, rather than overall survival. The latter is where the market seems confused, as direct and discrete treatments such as OSL cannot be effective in treating other metastasis, i.e., when the cancer has spread. A re-budgeting post IDE clarification, potential early sales post CE (Pierce Chow has foreshadowed this), a stronger board (Mr Roberts, likely just the start), under-owned institutionally and growing research should see the stock price continue to grow exponentially. Also could easily be a target as was SRX in the early days. I'm hoping not, as would like to ride this one out.
OSL Price at posting:
26.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)